Does J9256 require prior authorization?

Yes, J9256 requires prior authorization (high confidence). Code explicitly requires prior authorization.

What is the Medicare reimbursement rate for J9256?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

Backwork Sign up free

`J9256`, Injection, nipocalimab-aahu, 3 mg

HCPCS/CPT

Prior Authorization

Prior Auth Required

Code explicitly requires prior authorization (high confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

Submission of medical records (e.g., chart notes, laboratory values) confirming the required diagnostic and clinical criteria for initial therapy (drug-specific): diagnosis of gMG or CIDP as applicable, antibody test results (anti-AChR and/or anti-MuSK), MGFA Clinical Classification, MG-ADL total score at initiation.
For initial gMG therapy (Rystiggo): documentation that patient has not failed a previous course of Rystiggo therapy; positive serologic test for anti-AChR OR anti-MuSK antibodies; MGFA class II–IV at initiation; MG-ADL total score ≥ 5 at initiation; prior immunosuppressive therapy history (number and duration of agents failed) or history of required plasmapheresis/IVIG courses if applicable.
For initial gMG therapy (Vyvgart/Vyvgart Hytrulo): documentation that patient has not failed a previous course of Vyvgart or Vyvgart Hytrulo; positive serologic test for anti-AChR antibodies; MGFA class II–IV at initiation; MG-ADL total score ≥ 5 at initiation; prior immunosuppressive therapy history (number and duration of agents failed) or history of required plasmapheresis/IVIG courses if applicable.
For gMG continuation requests: medical records showing prior treatment with the specific agent and documentation of improvement and/or maintenance of at least a 2-point improvement in MG-ADL from pre-treatment baseline; reduction in signs and symptoms of myasthenia gravis; documentation re: IST doses (maintenance, reduction, or discontinuation) — note that IST add-on or escalation or additional rescue therapy from baseline while on FcRn blocker is considered treatment failure.
For CIDP initial requests (Vyvgart Hytrulo): documentation of progressive symptoms ≥ 2 months; evidence of symptomatic polyradiculoneuropathy with motor or sensory impairment in >1 limb; electrodiagnostic test results consistent with EFNS/PNS criteria showing at least one qualifying electrodiagnostic abnormality (motor distal latency prolongation in 2 nerves; reduction of motor conduction velocity in 2 nerves; prolongation of F-wave latency in 2 nerves; absence of F-waves in ≥1 nerve; partial motor conduction block in ≥1 motor nerve; abnormal temporal dispersion in ≥2 nerves; distal CMAP duration increase in ≥1 nerve).
For CIDP initial requests: documentation of trial and failure/contraindication/intolerance to corticosteroids (trial ≥ 2 months), AND either trial and failure to immune globulin (IVIG/SCIG) after a trial ≥ 3 months OR intolerance/contraindication to all immune globulins with documentation that dose was adjusted/escalated to maximally allowable/tolerated dose where applicable.

Key Coverage Criteria

Rystiggo (rozanolixizumab-noli) intravenous: Medically necessary for the treatment of generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody positive or anti-muscle-specific tyrosine kinase (MuSK) antibody positive when all Rystiggo coverage criteria are met (see limitations/documentation).
Vyvgart (efgartigimod alfa-fcab) intravenous: Medically necessary for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-AChR antibody positive when all Vyvgart coverage criteria are met (see limitations/documentation).
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) vial subcutaneous (medical benefit): Medically necessary for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-AChR antibody positive when all Vyvgart/Vyvgart Hytrulo coverage criteria are met (see limitations/documentation).
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for self-administered subcutaneous injection: Generally obtained under the pharmacy benefit (not medical benefit) unless member's benefit plan specifies otherwise; exception for UnitedHealthcare of California delegated provider groups (medical benefit prior authorization may apply).
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for chronic inflammatory demyelinating polyneuropathy (CIDP): Medically necessary for treatment of CIDP when all CIDP-specific coverage criteria are met (progressive symptoms ≥2 months, symptomatic polyradiculoneuropathy affecting >1 limb, required electrodiagnostic findings per EFNS/PNS, prior trials/failures/intolerance/contraindications to corticosteroids and immunoglobulin as specified, etc.).
Covered when hospital outpatient facility infusion services for specialty medications and IVIG/SCIG therapy are considered medically necessary and the member meets the specific clinical criteria described in the policy.

20 Active Policies

ARKBLUE-NIPOCALIMAB-E-G-IMAAVY-B6867BCB90, Nipocalimab (e.g., Imaavy)

FLORIDA_BLUE-FLBLUE-IMAAVY-NIPOCALIMAB-2CB0F2C762, Imaavy (nipocalimab)

BCBSLA-00942-28CA570133, 00942 nipocalimab-aahu (Imaavy)

BCBSM-2199424-1D19010E52, IMAAVY (NIPOCALIMAB-AAHU)

POINT32HEALTH-MDMNG-28411, Imaavy (nipocalimab)

MULTI

HEALTHPARTNERS-CC-ENTRY-252184, Neonatal Fc receptor antagonists (Vyvgart, Vyvgart Hytrulo, Rystiggo, Imaavy)

MULTI

POINT32HEALTH-MDMNG-25201, Imaavy (nipocalimab)

MULTI

POINT32HEALTH-MDMNG-24476, Imaavy (nipocalimab)

MULTI

BCBSNE-X-131-5053ACE7BD, ULTOMIRIS, PIASKY, UPLIZNA, EMPAVELI, PIASKY,RYSTIGGO, IMAAVY

MODA-IMAAVY-AC229CC72C, Imaavy (nipocalimab-aahu)

HEALTHNET_OR-HNOR-NIPOCALIMAB-AAHU-IMAAVY-CP-PHAR-720-BE4E5D50FA, Nipocalimab-aahu (Imaavy); CP.PHAR.720

IBX-COMMERCIAL-08-02-43-56EE611004, Nipocalimab-aahu (Imaavy)

IBX-MEDICARE-ADVANTAGE-MA08-187-C27776C9B9, Nipocalimab-aahu (Imaavy)

SUREST-POL-SUREST-fcrn-blockers, FcRn Blockers

AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-187-102C4E7CC8, Nipocalimab-aahu (Imaavy)

BCBSTN-c8889afe95, Nipocalimab-aahu (Imaavy)

EVICORE-MEDICAL_DRUG-69623F49CE37, Imaavy (nipocalimab-aahu intravenous infusion)

EVICORE-MEDICAL_DRUG-BA86B1833710, Imaavy (nipocalimab-aahu intravenous infusion)Effective 09/01/2026

UHC-POL-fcrn-blockers, FcRn Blockers

UHC-POL-provider-administered-drugs-soc, Provider Administered Drugs – Site of Care

Have a follow-up question?

Ask Backwork about documentation requirements, denial risks, or coverage in your state.

Ask Backwork about J9256 Sign up free

J9256, Injection, nipocalimab-aahu, 3 mg

HCPCS/CPT

Prior Authorization

Prior Auth Required

Code explicitly requires prior authorization (high confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

Submission of medical records (e.g., chart notes, laboratory values) confirming the required diagnostic and clinical criteria for initial therapy (drug-specific): diagnosis of gMG or CIDP as applicable, antibody test results (anti-AChR and/or anti-MuSK), MGFA Clinical Classification, MG-ADL total score at initiation.
For initial gMG therapy (Rystiggo): documentation that patient has not failed a previous course of Rystiggo therapy; positive serologic test for anti-AChR OR anti-MuSK antibodies; MGFA class II–IV at initiation; MG-ADL total score ≥ 5 at initiation; prior immunosuppressive therapy history (number and duration of agents failed) or history of required plasmapheresis/IVIG courses if applicable.
For initial gMG therapy (Vyvgart/Vyvgart Hytrulo): documentation that patient has not failed a previous course of Vyvgart or Vyvgart Hytrulo; positive serologic test for anti-AChR antibodies; MGFA class II–IV at initiation; MG-ADL total score ≥ 5 at initiation; prior immunosuppressive therapy history (number and duration of agents failed) or history of required plasmapheresis/IVIG courses if applicable.
For gMG continuation requests: medical records showing prior treatment with the specific agent and documentation of improvement and/or maintenance of at least a 2-point improvement in MG-ADL from pre-treatment baseline; reduction in signs and symptoms of myasthenia gravis; documentation re: IST doses (maintenance, reduction, or discontinuation) — note that IST add-on or escalation or additional rescue therapy from baseline while on FcRn blocker is considered treatment failure.
For CIDP initial requests (Vyvgart Hytrulo): documentation of progressive symptoms ≥ 2 months; evidence of symptomatic polyradiculoneuropathy with motor or sensory impairment in >1 limb; electrodiagnostic test results consistent with EFNS/PNS criteria showing at least one qualifying electrodiagnostic abnormality (motor distal latency prolongation in 2 nerves; reduction of motor conduction velocity in 2 nerves; prolongation of F-wave latency in 2 nerves; absence of F-waves in ≥1 nerve; partial motor conduction block in ≥1 motor nerve; abnormal temporal dispersion in ≥2 nerves; distal CMAP duration increase in ≥1 nerve).
For CIDP initial requests: documentation of trial and failure/contraindication/intolerance to corticosteroids (trial ≥ 2 months), AND either trial and failure to immune globulin (IVIG/SCIG) after a trial ≥ 3 months OR intolerance/contraindication to all immune globulins with documentation that dose was adjusted/escalated to maximally allowable/tolerated dose where applicable.

Key Coverage Criteria

Rystiggo (rozanolixizumab-noli) intravenous: Medically necessary for the treatment of generalized myasthenia gravis (gMG) in patients who are anti-acetylcholine receptor (AChR) antibody positive or anti-muscle-specific tyrosine kinase (MuSK) antibody positive when all Rystiggo coverage criteria are met (see limitations/documentation).
Vyvgart (efgartigimod alfa-fcab) intravenous: Medically necessary for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-AChR antibody positive when all Vyvgart coverage criteria are met (see limitations/documentation).
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) vial subcutaneous (medical benefit): Medically necessary for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-AChR antibody positive when all Vyvgart/Vyvgart Hytrulo coverage criteria are met (see limitations/documentation).
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for self-administered subcutaneous injection: Generally obtained under the pharmacy benefit (not medical benefit) unless member's benefit plan specifies otherwise; exception for UnitedHealthcare of California delegated provider groups (medical benefit prior authorization may apply).
Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for chronic inflammatory demyelinating polyneuropathy (CIDP): Medically necessary for treatment of CIDP when all CIDP-specific coverage criteria are met (progressive symptoms ≥2 months, symptomatic polyradiculoneuropathy affecting >1 limb, required electrodiagnostic findings per EFNS/PNS, prior trials/failures/intolerance/contraindications to corticosteroids and immunoglobulin as specified, etc.).
Covered when hospital outpatient facility infusion services for specialty medications and IVIG/SCIG therapy are considered medically necessary and the member meets the specific clinical criteria described in the policy.

20 Active Policies

ARKBLUE-NIPOCALIMAB-E-G-IMAAVY-B6867BCB90, Nipocalimab (e.g., Imaavy)

FLORIDA_BLUE-FLBLUE-IMAAVY-NIPOCALIMAB-2CB0F2C762, Imaavy (nipocalimab)

BCBSLA-00942-28CA570133, 00942 nipocalimab-aahu (Imaavy)

BCBSM-2199424-1D19010E52, IMAAVY (NIPOCALIMAB-AAHU)

POINT32HEALTH-MDMNG-28411, Imaavy (nipocalimab)

MULTI

HEALTHPARTNERS-CC-ENTRY-252184, Neonatal Fc receptor antagonists (Vyvgart, Vyvgart Hytrulo, Rystiggo, Imaavy)

MULTI

POINT32HEALTH-MDMNG-25201, Imaavy (nipocalimab)

MULTI

POINT32HEALTH-MDMNG-24476, Imaavy (nipocalimab)

MULTI

BCBSNE-X-131-5053ACE7BD, ULTOMIRIS, PIASKY, UPLIZNA, EMPAVELI, PIASKY,RYSTIGGO, IMAAVY

MODA-IMAAVY-AC229CC72C, Imaavy (nipocalimab-aahu)

HEALTHNET_OR-HNOR-NIPOCALIMAB-AAHU-IMAAVY-CP-PHAR-720-BE4E5D50FA, Nipocalimab-aahu (Imaavy); CP.PHAR.720

IBX-COMMERCIAL-08-02-43-56EE611004, Nipocalimab-aahu (Imaavy)

IBX-MEDICARE-ADVANTAGE-MA08-187-C27776C9B9, Nipocalimab-aahu (Imaavy)

SUREST-POL-SUREST-fcrn-blockers, FcRn Blockers

AMERIHEALTH-MEDICARE-ADVANTAGE-MA08-187-102C4E7CC8, Nipocalimab-aahu (Imaavy)

BCBSTN-c8889afe95, Nipocalimab-aahu (Imaavy)

EVICORE-MEDICAL_DRUG-69623F49CE37, Imaavy (nipocalimab-aahu intravenous infusion)

EVICORE-MEDICAL_DRUG-BA86B1833710, Imaavy (nipocalimab-aahu intravenous infusion)Effective 09/01/2026

UHC-POL-fcrn-blockers, FcRn Blockers

UHC-POL-provider-administered-drugs-soc, Provider Administered Drugs – Site of Care

Have a follow-up question?

Ask Backwork about documentation requirements, denial risks, or coverage in your state.

Ask Backwork about J9256 Sign up free

`J9256`, Injection, nipocalimab-aahu, 3 mg

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

`J9256`, Injection, nipocalimab-aahu, 3 mg

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

J9256, Injection, nipocalimab-aahu, 3 mg

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

J9256, Injection, nipocalimab-aahu, 3 mg

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

`J9256`, Injection, nipocalimab-aahu, 3 mg

`J9256`, Injection, nipocalimab-aahu, 3 mg